These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 33513726)

  • 1. Evolution, Clinical and Microbiological Characteristics of Invasive Pneumococcal Disease since the Introduction of the Pneumococcal Conjugate Vaccine 13-Valent in Adults over 18 Years Old.
    Buades J; Losada I; González-Moreno J; Peñaranda M; Vilaplana L; Roda N; Rey A; Rodriguez A; Garau M; de Gopegui ER; Serra A; Saurina J; Payeras A
    Vaccines (Basel); 2021 Jan; 9(2):. PubMed ID: 33513726
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evolution of pneumococcal infections in adult patients during a four-year period after vaccination of a pediatric population with 13-valent pneumococcal conjugate vaccine.
    Payeras A; Villoslada A; Garau M; Salvador MN; Gallegos MC
    Int J Infect Dis; 2015 Apr; 33():22-7. PubMed ID: 25541296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Epidemiological features of invasive pneumococcal disease before and after the introduction of pneumococcal conjugate vaccine in Gran Canaria (Canary Islands)].
    Artiles F; Horcajada I; Cañas AM; Alamo I; Bordes A; González A; Santana M; Lafarga B
    Enferm Infecc Microbiol Clin; 2009 Jan; 27(1):14-21. PubMed ID: 19217998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway.
    Steens A; Bergsaker MA; Aaberge IS; Rønning K; Vestrheim DF
    Vaccine; 2013 Dec; 31(52):6232-8. PubMed ID: 24176490
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pneumococcal carriage and invasive disease in children before introduction of the 13-valent conjugate vaccine: comparison with the era before 7-valent conjugate vaccine.
    Sharma D; Baughman W; Holst A; Thomas S; Jackson D; da Gloria Carvalho M; Beall B; Satola S; Jerris R; Jain S; Farley MM; Nuorti JP
    Pediatr Infect Dis J; 2013 Feb; 32(2):e45-53. PubMed ID: 23080290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of the changing pneumococcal national immunisation program among older Australians.
    Menzies R; Stein AN; Booy R; Van Buynder PG; Litt J; Cripps AW
    Vaccine; 2021 Jan; 39(4):720-728. PubMed ID: 33384189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The direct effect of pneumococcal conjugate vaccines on invasive pneumococcal disease in children in the Latin American and Caribbean region (SIREVA 2006-17): a multicentre, retrospective observational study.
    Agudelo CI; Castañeda-Orjuela C; Brandileone MCC; Echániz-Aviles G; Almeida SCG; Carnalla-Barajas MN; Regueira M; Fossati S; Alarcón P; Araya P; Duarte C; Sánchez J; Novas M; Toraño-Peraza G; Rodríguez-Ortega M; Chamorro-Cortesi G; Kawabata A; García-Gabarrot G; Camou T; Spadola E; Payares D; Andrade AL; Di Fabio JL; Castañeda E;
    Lancet Infect Dis; 2021 Mar; 21(3):405-417. PubMed ID: 32986996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of pneumococcal conjugate vaccines on the incidence of invasive pneumococcal disease caused by ten non-vaccine serotypes in Denmark.
    Slotved HC; Dalby T; Hoffmann S
    Vaccine; 2016 Feb; 34(6):769-74. PubMed ID: 26772630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term Impact of a "3 + 0" Schedule for 7- and 13-Valent Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease in Australia, 2002-2014.
    Jayasinghe S; Menzies R; Chiu C; Toms C; Blyth CC; Krause V; McIntyre P
    Clin Infect Dis; 2017 Jan; 64(2):175-183. PubMed ID: 27986682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serotype distribution and antimicrobial susceptibility of invasive Streptococcus pneumoniae isolates among adult and elderly population before and after introduction of pneumococcal conjugate vaccine in Casablanca, Morocco.
    Nzoyikorera N; Diawara I; Katfy M; Katfy K; Maaloum F; Nyandwi J; Belabbes H; Elmdaghri N; Zerouali K
    BMC Infect Dis; 2023 Jan; 23(1):24. PubMed ID: 36639755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Public health impact of pneumococcal conjugate vaccine infant immunization programs: assessment of invasive pneumococcal disease burden and serotype distribution.
    Izurieta P; Bahety P; Adegbola R; Clarke C; Hoet B
    Expert Rev Vaccines; 2018 Jun; 17(6):479-493. PubMed ID: 29241390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dynamics of Invasive Pneumococcal Disease in Israel in Children and Adults in the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Era: A Nationwide Prospective Surveillance.
    Ben-Shimol S; Regev-Yochay G; Givon-Lavi N; van der Beek BA; Brosh-Nissimov T; Peretz A; Megged O; Dagan R; ;
    Clin Infect Dis; 2022 May; 74(9):1639-1649. PubMed ID: 34293091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early impact of sequential introduction of 7-valent and 13-valent pneumococcal conjugate vaccine on IPD in Israeli children <5 years: an active prospective nationwide surveillance.
    Ben-Shimol S; Greenberg D; Givon-Lavi N; Schlesinger Y; Somekh E; Aviner S; Miron D; Dagan R
    Vaccine; 2014 Jun; 32(27):3452-9. PubMed ID: 24690148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pediatric invasive pneumococcal disease in Taiwan following a national catch-up program with the 13-valent pneumococcal conjugate vaccine.
    Wei SH; Chiang CS; Chiu CH; Chou P; Lin TY
    Pediatr Infect Dis J; 2015 Mar; 34(3):e71-7. PubMed ID: 25247584
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Health and economic burden associated with 15-valent pneumococcal conjugate vaccine serotypes in children in the United States.
    Hu T; Weiss T; Owusu-Edusei K; Petigara T
    J Med Econ; 2020 Dec; 23(12):1653-1660. PubMed ID: 33084447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of Antibiotic-Nonsusceptible Invasive Pneumococcal Disease With the 13-Valent Pneumococcal Conjugate Vaccine.
    Tomczyk S; Lynfield R; Schaffner W; Reingold A; Miller L; Petit S; Holtzman C; Zansky SM; Thomas A; Baumbach J; Harrison LH; Farley MM; Beall B; McGee L; Gierke R; Pondo T; Kim L
    Clin Infect Dis; 2016 May; 62(9):1119-25. PubMed ID: 26908787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trends of invasive pneumococcal disease and its serotypes in the Autonomous Community of Madrid.
    Latasa Zamalloa P; Sanz Moreno JC; Ordobás Gavín M; Barranco Ordoñez MD; Insúa Marisquerena E; Gil de Miguel Á; Fernández Chávez AC; García-Comas L
    Enferm Infecc Microbiol Clin (Engl Ed); 2018 Dec; 36(10):612-620. PubMed ID: 29221826
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV Infection and the Epidemiology of Invasive Pneumococcal Disease (IPD) in South African Adults and Older Children Prior to the Introduction of a Pneumococcal Conjugate Vaccine (PCV).
    Meiring S; Cohen C; Quan V; de Gouveia L; Feldman C; Karstaedt A; Klugman KP; Madhi SA; Rabie H; Sriruttan C; von Gottberg A;
    PLoS One; 2016; 11(2):e0149104. PubMed ID: 26863135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of 23-Valent Pneumococcal Polysaccharide Vaccine against Invasive Pneumococcal Disease in Adults, Japan, 2013-2017.
    Shimbashi R; Suzuki M; Chang B; Watanabe H; Tanabe Y; Kuronuma K; Oshima K; Maruyama T; Takeda H; Kasahara K; Fujita J; Nishi J; Kubota T; Tanaka-Taya K; Matsui T; Sunagawa T; Oishi K;
    Emerg Infect Dis; 2020 Oct; 26(10):2378-2386. PubMed ID: 32946721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidemiology of invasive pneumococcal disease among adult patients in barcelona before and after pediatric 7-valent pneumococcal conjugate vaccine introduction, 1997-2007.
    Ardanuy C; Tubau F; Pallares R; Calatayud L; Domínguez MA; Rolo D; Grau I; Martín R; Liñares J
    Clin Infect Dis; 2009 Jan; 48(1):57-64. PubMed ID: 19035779
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.